The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Tvardi Therapeutics’ TTI-101 for the treatment of idiopathic pulmonary fibrosis (IPF). TTI-101 is a small molecule, given orally, that acts as a direct inhibitor of STAT3, an inflammatory protein that plays a role in the…
Abnormally high levels of the signaling molecule interleukin 19 (IL-19) were detected in lung tissues from both mice and humans with idiopathic pulmonary fibrosis (IPF) in a recent study. These findings indicate that IL-19 promotes IPF progression by activating the transforming growth factor-beta pathway, a key mediator of tissue…
Supplementary oxygen using a high‐flow nasal cannula boosts exercise endurance more effectively than standard devices in idiopathic pulmonary fibrosis (IPF) patients with suboptimal blood-oxygen levels, a small trial reported. The study, “Impact of high-flow oxygen therapy during exercise in idiopathic pulmonary fibrosis: a pilot crossover clinical trial,” was…
In commemoration of the International Quality of Life Month happening in January, the Pulmonary Fibrosis Foundation (PFF) is calling attention to the educational resources it offers, which are designed to support and improve the lives of people with pulmonary fibrosis (PF). “This January, start the New Year on…
The first patient has been enrolled in a pivotal Phase 2b trial investigating the safety and effectiveness of Horizon Therapeutics’ oral medicine candidate HZN-825 in people with idiopathic pulmonary fibrosis (IPF). The trial (NCT05032066) aims to enroll approximately 360 people with IPF, ages 18–80, whose disease symptoms…
PF Warriors has partnered with online shopping site Joe & Bella to make holiday gift-giving easier for people with pulmonary fibrosis (PF) — while raising funds for the nonprofit’s mission of increasing awareness of PF and other interstitial lung diseases (ILDs). Products sold at Joe & Bella…
A Phase 1 trial assessing how cudetaxestat, an investigational treatment for idiopathic pulmonary fibrosis (IPF), interacts with two approved IPF treatments, Ofev (nintedanib) and Esbriet (pirfenidone), is now enrolling healthy volunteers, Blade Therapeutics, the therapy’s developer, announced. The trial (NCT04939467) is aiming to enroll 86 healthy adults, ages 18 to 55.
Treatment with N115, EmphyCorp’s non-steroidal nasal spray, led to statistically and clinically significant improvements across all lung function parameters in patients with pulmonary fibrosis (PF) participating in a Phase 3 trial, data show. Now, data from two other Phase 3 clinical trials suggest that N115 also may be…
Long-term exposure to air pollutants — nitrogen dioxide, ozone, and fine particle matter — appears to greatly raise the risk of acute exacerbations, or sudden bouts of symptom worsening, in people with idiopathic pulmonary fibrosis (IPF), a study of patients in Greece reported. “Our findings show consistent positive associations” between…
A large and multi-ethnic database, reported to be the first of its kind for rare lung diseases, is now compiling real-world clinical and imaging data on people with pulmonary fibrosis (PF) and other interstitial lung diseases (ILDs) from centers across the globe. Launched by the Open Source Imaging Consortium (OSIC),…
Get regular updates to your inbox.
